Matches in Wikidata for { <http://www.wikidata.org/entity/Q58097435> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- Q58097435 description "artículu científicu espublizáu en payares de 2018" @default.
- Q58097435 description "im Oktober 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q58097435 description "scientific article published on 13 November 2018" @default.
- Q58097435 description "wetenschappelijk artikel" @default.
- Q58097435 description "наукова стаття, опублікована в жовтні 2018" @default.
- Q58097435 name "Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid Based Formulations" @default.
- Q58097435 name "Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid Based Formulations" @default.
- Q58097435 type Item @default.
- Q58097435 label "Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid Based Formulations" @default.
- Q58097435 label "Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid Based Formulations" @default.
- Q58097435 prefLabel "Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid Based Formulations" @default.
- Q58097435 prefLabel "Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid Based Formulations" @default.
- Q58097435 P1433 Q58097435-3E273D82-7665-434B-A1BC-AD6B0D1E404A @default.
- Q58097435 P1476 Q58097435-36C90206-D7B3-4830-9165-8E891EAF5B9A @default.
- Q58097435 P2093 Q58097435-173934A5-EB25-4C45-9FC6-FB5D9161FC25 @default.
- Q58097435 P2093 Q58097435-2CD488EE-680F-42FF-8276-1115B903F491 @default.
- Q58097435 P2093 Q58097435-41ACE100-80EE-4CB0-94EE-810F92336C1C @default.
- Q58097435 P2093 Q58097435-4E295678-024B-4196-AEC3-B34D3991FA44 @default.
- Q58097435 P2093 Q58097435-9FE15E55-95BF-4924-AFE9-54CF5BA52D3B @default.
- Q58097435 P2093 Q58097435-9FF30ECE-5FFC-4903-A8EC-6D7ED9024D30 @default.
- Q58097435 P2093 Q58097435-AB0F5D7F-6AD8-4F4F-83B4-B49D5648A755 @default.
- Q58097435 P304 Q58097435-391CCE76-D64E-47D9-8632-5CD19276D303 @default.
- Q58097435 P31 Q58097435-AA9D5D8A-5574-40D3-A8F0-A575FBE5C635 @default.
- Q58097435 P356 Q58097435-BC8049D1-FAB5-4F3E-BDD4-EB7F9347B80C @default.
- Q58097435 P407 Q58097435-EE9071E2-4737-451F-A29A-47F6C82F867F @default.
- Q58097435 P433 Q58097435-BF59773E-80C9-4EEE-AA69-90B6B9381F16 @default.
- Q58097435 P478 Q58097435-3F99FD71-DF70-4A55-B104-C81A497A2524 @default.
- Q58097435 P50 Q58097435-1C03ACDF-DC22-4F2D-9A50-38C55746BC41 @default.
- Q58097435 P50 Q58097435-30E2DDEB-503C-4A52-83CA-F6378CD9B433 @default.
- Q58097435 P50 Q58097435-9A30453D-8065-4837-AE9C-102DE37F797B @default.
- Q58097435 P50 Q58097435-FFA867A5-286A-4EB9-AF40-30140E83BC7D @default.
- Q58097435 P577 Q58097435-0B2AFEC6-5DB8-4882-AE0B-9978D24F92F0 @default.
- Q58097435 P698 Q58097435-4CE790FC-0EA4-4A00-AC88-5D0E2793CE21 @default.
- Q58097435 P356 ACS.MOLPHARMACEUT.8B00858 @default.
- Q58097435 P698 30376336 @default.
- Q58097435 P1433 Q3011140 @default.
- Q58097435 P1476 "Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations" @default.
- Q58097435 P2093 "David M Shackleford" @default.
- Q58097435 P2093 "David T Vodak" @default.
- Q58097435 P2093 "Hassan Benameur" @default.
- Q58097435 P2093 "Kristian J Tangso" @default.
- Q58097435 P2093 "Leigh Ford" @default.
- Q58097435 P2093 "Shea Lim" @default.
- Q58097435 P2093 "Sifei Han" @default.
- Q58097435 P304 "5678-5696" @default.
- Q58097435 P31 Q13442814 @default.
- Q58097435 P356 "10.1021/ACS.MOLPHARMACEUT.8B00858" @default.
- Q58097435 P407 Q1860 @default.
- Q58097435 P433 "12" @default.
- Q58097435 P478 "15" @default.
- Q58097435 P50 Q38804793 @default.
- Q58097435 P50 Q46042717 @default.
- Q58097435 P50 Q62833120 @default.
- Q58097435 P50 Q92670346 @default.
- Q58097435 P577 "2018-11-13T00:00:00Z" @default.
- Q58097435 P698 "30376336" @default.